Spectrophotometric determination of fluoxetine by batch and flow injection methods

被引:20
作者
Afkhami, Abbas [1 ]
Madrakian, Tayyebeh [1 ]
Khalafi, Lida [1 ]
机构
[1] Bu Ali Sina Univ, Fac Chem, Hamadan 65174, Iran
关键词
competitive complexation; fluoxetine determination; inclusion complex; beta-cyclodextrin; flow injection analysis (FIA); pharmaceuticals; UV/VIS;
D O I
10.1248/cpb.54.1642
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A rapid, simple, and accurate spectrophotometric method is presented for the determination of fluoxetine by batch and flow injection analysis methods. The method is based on fluoxetine competitive complexation reaction with phenolphthalein-beta-cyclodextrin (PHP-beta-CD) inclusion complex. The increase in the absorbance of the solution at 554 urn by the addition of fluoxetine was measured. The formation constant for fluoxetin-beta-CD was calculated by non-linear least squares fitting. Fluoxetine can be determined in the range 7.0x10(-6)-2.4 x 10(-4) mol l(-1) and 5.0x10(-5)-1.0x10(-2) mol l(-1) by batch and flow methods, respectively. The limit of detection and limit of quantification were respectively 4.13x10(-6) mol l(-1) and 1.38 x 10(-5) mol l(-1) for batch and 2.46 x 10(-5) mol l(-1) and 8.22 x 10(-5) mol l(-1) for flow method. The sampling rate in flow injection analysis method was 80 +/- 5 samples h(-1). The method was applied to the determination of fluoxetine in pharmaceutical formulations and after addition to human urine samples.
引用
收藏
页码:1642 / 1646
页数:5
相关论文
共 26 条
[1]   Spectrophotometric determination of conditional acidity constant as a function of β-cyclodextrin concentration for some organic acids using rank annihilation factor analysis [J].
Afkhami, A ;
Khalafi, L .
ANALYTICA CHIMICA ACTA, 2006, 569 (1-2) :267-274
[2]  
ATMACA S, 1995, PHARMAZIE, V50, P300
[3]   CLINICAL-PHARMACOLOGY AND PHARMACOKINETICS OF FLUOXETINE - A REVIEW [J].
BERGSTROM, RF ;
LEMBERGER, L ;
FARID, NA ;
WOLEN, RL .
BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 :47-50
[4]   Cyclodextrin enhanced spectrofluorimetric determination of fluoxetine in pharmaceuticals and biological fluids [J].
Berzas, JJ ;
Alañón, A ;
Lázaro, JA .
TALANTA, 2002, 58 (02) :301-309
[5]  
BERZAS JJ, 2000, ANAL CHIM ACTA, V417, P169
[6]  
BEUFIELD P, 1985, DRUGS, V32, P48
[7]  
Buzinkaiová T, 2000, ELECTROPHORESIS, V21, P2839
[8]   Fluoxetine - A review of its therapeutic potential in the treatment of depression associated with physical illness [J].
Cheer, SM ;
Goa, KL .
DRUGS, 2001, 61 (01) :81-110
[9]  
Djordjevic S., 2005, Farmaco (Lausanne), V60, P345, DOI 10.1016/j.farmac.2005.01.002
[10]  
DUCHENE D, 1992, NEW TRENDS CYCLODEXT, P351